Priyanka Rohatgi
Partner at Novo Holdings
Greater Boston
Overview
Work Experience
Partner
2022 - Current
Board Observer
2021 - 2022
Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas.
Raised $154,383,867.00 from Penn Medicine Co-Investment Program, Agent Capital, The Mark Foundation for Cancer Research, Cormorant Asset Management, Quan Capital, BrightEdge Fund, OUP (Osage University Partners), RA Capital Management, Logos Capital and Pfizer Venture Investments.
Venture Partner
2021 - 2022
Longwood Fund finances science-based companies that develop novel solutions for medical problems.
Board Observer
2020 - 2021
Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.
Raised $244,300,000.00 from Bain Capital Life Sciences and Rock Springs Capital.
Board Member
2019 - 2021
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Raised $224,000,000.00 from StemPoint Capital, Deep Track Capital, Blue Owl, Ridgeback Capital and Laurion Capital Management.
Managing Director, Head of Ipsen Ventures
2018 - 2021
Investment Director, AbbVie Ventures
2016 - 2018
AbbVie is a pharmaceutical company that discovers, develops, and markets medicines.
Raised $15,000,249,999.00.
Board Member
2015 - 2016
Board Member
2014 - 2015
Opsonix is a developer of a pathogen-extracting therapy designed to transform the treatment of bloodstream infections and sepsis.
Raised $9,250,000.00 from Baxter Ventures.
Board Member
2014 - 2015